Dexcel Pharma formed part of a consortium that has supplied $80.5m in series A financing to Kriya Therapeutics, a gene therapy developer exploiting Stanford University research.

Kriya Therapeutics, a US-based developer of gene therapies based on research at Stanford University, secured $80.5m in a series A round yesterday backed by pharmaceutical firm Dexcel Pharma.
QVT Financial, Foresite Capital, Bluebird Ventures, Narya Capital, Amplo, Asia Alpha, Transhuman Capital and private investor Paul Manning also contributed.
Kriya Therapeutics is working on gene therapies for conditions where the underlying biology is well-understood, targeting indications such as type 1 and 2 diabetes and severe obesity. The company hopes…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in